{"id":"flublok","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain"},{"rate":"10-15","effect":"Injection site erythema"},{"rate":"5-10","effect":"Injection site swelling"},{"rate":"10-15","effect":"Myalgia"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":null,"_dailymed":{"setId":"0c3cd915-babe-49c0-8aac-bf0247a17f3e","title":"FLUBLOK TRIVALENT NORTHERN HEMISPHERE (INFLUENZA A VIRUS A/WEST VIRGINIA/30/2022 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/DISTRICT OF COLUMBIA/27/2023 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, AND INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 RECOMBINANT HEMAGGLUTININ ANTIGEN) INJECTION [SANOFI PASTEUR INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FluBlok uses recombinant hemagglutinin (HA) protein produced in insect cells (baculovirus expression system) rather than egg-based or cell culture methods. This allows rapid production of vaccine antigens matching circulating influenza strains, triggering both humoral and cellular immune responses to prevent influenza infection.","oneSentence":"FluBlok is a recombinant influenza vaccine that stimulates immune response against influenza virus surface antigens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:39.481Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Protein_Sciences","title":"Protein Sciences","extract":"Protein Sciences Corporation is a biotech company based in Meriden, Connecticut. The company develops and produces vaccines and biopharmaceuticals for use against influenza and other diseases. In 2017, the company was acquired by Sanofi for $750 million."},"indications":{"approved":[{"name":"Prevention of influenza A and B in adults aged 18 years and older"}]},"trialDetails":[{"nctId":"NCT07365826","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-01-12","conditions":"Pneumococcal Vaccines","enrollment":1300},{"nctId":"NCT02872311","phase":"NA","title":"Open-Label Influenza Vaccine Evaluation","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2016-09","conditions":"Immune Response","enrollment":179},{"nctId":"NCT07240922","phase":"PHASE4","title":"The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-10-01","conditions":"Influenza","enrollment":600},{"nctId":"NCT03598439","phase":"PHASE4","title":"Randomized Influenza Vaccine Evaluation of Immune Response","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2018-07-30","conditions":"Influenza","enrollment":366},{"nctId":"NCT05479370","phase":"PHASE3","title":"Immunogenicity Trial of 3 Influenza Vaccines","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2022-09-29","conditions":"Influenza Vaccination","enrollment":366},{"nctId":"NCT03945825","phase":"PHASE1","title":"Flublok or Fluzone With Advax-CpG55.2 or AF03","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-06-10","conditions":"Influenza, Influenza Immunisation","enrollment":241},{"nctId":"NCT05829356","phase":"PHASE1","title":"Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-04-12","conditions":"Influenza Immunization","enrollment":159},{"nctId":"NCT05513053","phase":"PHASE3","title":"Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-10-27","conditions":"Influenza Immunization","enrollment":1308},{"nctId":"NCT05513391","phase":"PHASE3","title":"Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-10","conditions":"Influenza Immunization","enrollment":366},{"nctId":"NCT06361875","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-04-01","conditions":"Influenza Immunization","enrollment":910},{"nctId":"NCT06518577","phase":"PHASE4","title":"Immunogenicity of Influenza Vaccinations","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-09","conditions":"Influenza","enrollment":605},{"nctId":"NCT06015282","phase":"PHASE3","title":"The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-11-03","conditions":"Influenza, Human","enrollment":7741},{"nctId":"NCT03694392","phase":"","title":"Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2018-09-16","conditions":"Influenza, Pneumonia, Lower Respiratory Tract Infection","enrollment":2776278},{"nctId":"NCT05514002","phase":"PHASE4","title":"Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years","status":"TERMINATED","sponsor":"Fatimah Dawood","startDate":"2022-09-13","conditions":"Influenza, Human","enrollment":3988},{"nctId":"NCT05650554","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-12-12","conditions":"Influenza Immunization","enrollment":682},{"nctId":"NCT05624606","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-28","conditions":"Influenza Immunization","enrollment":682},{"nctId":"NCT05553301","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-10-03","conditions":"Influenza Immunization","enrollment":560},{"nctId":"NCT05518500","phase":"PHASE4","title":"A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults","status":"RECRUITING","sponsor":"The Jackson Laboratory","startDate":"2022-08-31","conditions":"Aging, Influenza Vaccine, Dendritic Cell","enrollment":75},{"nctId":"NCT03722589","phase":"PHASE4","title":"Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2018-09-12","conditions":"Influenza","enrollment":944},{"nctId":"NCT04576377","phase":"PHASE4","title":"Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2020-10-05","conditions":"Influenza, Human","enrollment":977},{"nctId":"NCT03330132","phase":"PHASE4","title":"Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2017-10-07","conditions":"Influenza, Human","enrollment":1861},{"nctId":"NCT03734237","phase":"PHASE4","title":"A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD","status":"UNKNOWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2018-11-06","conditions":"Influenza, Influenza-like Illness, Influenza Vaccines","enrollment":15449},{"nctId":"NCT04523324","phase":"PHASE4","title":"Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2019-10-31","conditions":"Influenza","enrollment":577},{"nctId":"NCT06118151","phase":"PHASE1","title":"Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-04-11","conditions":"Influenza, Influenza Immunization","enrollment":388},{"nctId":"NCT04484532","phase":"EARLY_PHASE1","title":"Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2017-10-17","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":130},{"nctId":"NCT03965195","phase":"PHASE4","title":"Recombinant Influenza Vaccination in U.S. Nursing Homes","status":"UNKNOWN","sponsor":"Insight Therapeutics, LLC","startDate":"2019-07-20","conditions":"Influenza, Influenza -Like Illness, Influenza, Human","enrollment":1989},{"nctId":"NCT03969641","phase":"PHASE4","title":"Safety of RIV4 Versus IIV4 in Pregnant Women","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-09-05","conditions":"Safety, Adverse Event Following Immunisation, Birth Outcomes","enrollment":384},{"nctId":"NCT03658629","phase":"PHASE2","title":"Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults","status":"TERMINATED","sponsor":"Novavax","startDate":"2018-09-24","conditions":"Influenza, Human","enrollment":1375},{"nctId":"NCT04077424","phase":"PHASE4","title":"Senescent Immunity in Elders and Vaccine Responses (SILVER)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-10-21","conditions":"Flu Vaccine","enrollment":10},{"nctId":"NCT04460781","phase":"","title":"Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Influenza","enrollment":96175},{"nctId":"NCT00539981","phase":"PHASE3","title":"Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09-15","conditions":"Influenza","enrollment":4648},{"nctId":"NCT03617523","phase":"PHASE4","title":"Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-10","conditions":"Influenza","enrollment":240},{"nctId":"NCT03068949","phase":"PHASE4","title":"Comparison of Three Licensed Influenza Vaccines","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2015-10-28","conditions":"Influenza","enrollment":413},{"nctId":"NCT02747407","phase":"","title":"Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-05","conditions":"Astrocytoma, Glioma, Oligodendroglioma","enrollment":55},{"nctId":"NCT02544880","phase":"PHASE1","title":"PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC","status":"COMPLETED","sponsor":"Donald T. Weed, MD, FACS","startDate":"2016-04-25","conditions":"Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":16},{"nctId":"NCT03460743","phase":"PHASE3","title":"Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.","status":"COMPLETED","sponsor":"Laboratorios Liomont","startDate":"2018-03-22","conditions":"Influenza, Human","enrollment":1556},{"nctId":"NCT02285998","phase":"PHASE3","title":"Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2014-10","conditions":"Influenza","enrollment":9003},{"nctId":"NCT02600585","phase":"","title":"Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2015-11","conditions":"Human Influenza","enrollment":254648},{"nctId":"NCT02290509","phase":"PHASE3","title":"Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2014-10","conditions":"Influenza","enrollment":1350},{"nctId":"NCT01959945","phase":"PHASE3","title":"Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2013-11","conditions":"Influenza","enrollment":219},{"nctId":"NCT01825200","phase":"PHASE3","title":"Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2013-03","conditions":"Influenza","enrollment":2640},{"nctId":"NCT00539864","phase":"PHASE3","title":"Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2007-09","conditions":"Influenza","enrollment":602},{"nctId":"NCT01195038","phase":"PHASE2","title":"Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults","status":"COMPLETED","sponsor":"UMN Pharma Inc.","startDate":"2010-10","conditions":"Influenza","enrollment":87},{"nctId":"NCT00980447","phase":"PHASE2","title":"Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults","status":"COMPLETED","sponsor":"UMN Pharma Inc.","startDate":"2009-10","conditions":"Influenza, Virus Diseases","enrollment":90},{"nctId":"NCT00328107","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2004-11","conditions":"Influenza","enrollment":459},{"nctId":"NCT00395174","phase":"PHASE3","title":"Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2006-10","conditions":"Influenza","enrollment":870},{"nctId":"NCT00336453","phase":"PHASE1, PHASE2","title":"Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2006-10","conditions":"Influenza","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rHA Trivalent Recombinant Hemagglutinin Influenza Vaccine"],"phase":"marketed","status":"active","brandName":"FluBlok","genericName":"FluBlok","companyName":"The University of Hong Kong","companyId":"the-university-of-hong-kong","modality":"Biologic","firstApprovalDate":"","aiSummary":"FluBlok is a recombinant influenza vaccine that stimulates immune response against influenza virus surface antigens. Used for Prevention of influenza A and B in adults aged 18 years and older.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}